10-Q: Paysign Reports Strong Q2 2026 Growth

Paysign, Inc. announced a substantial increase in revenues and net income for the second quarter of 2026, driven by strong performance in its plasma and pharma industry segments.

Summary

• Paysign, Inc. reported significant financial improvements for the second quarter and first half of 2026 compared to the prior year.
• Total revenues increased by 48.1% to $28.3 million for Q2 2026 and by 49.4% to $56.3 million for the first half of 2026.
• Net income surged by 386.9% to $6.8 million for Q2 2026 and by 206.9% to $12.2 million for the first half of 2026.
• Gross profit margins improved to 63.3% in Q2 2026 and 64.2% in the first half of 2026.
• The company generated strong operating cash flow of $20.1 million in the first half of 2026, a significant improvement from a negative $2.4 million in the prior year period.
• Cash and restricted cash increased to $176.5 million as of June 30, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to significant revenue growth, improved profitability, and strong cash flow generation, indicating robust operational performance and a healthy financial outlook.

Positives

• Total revenues grew by 48.1% to $28.3 million in Q2 2026 and 49.4% to $56.3 million in the first half of 2026.
• Net income saw a substantial increase of 386.9% to $6.8 million in Q2 2026 and 206.9% to $12.2 million in the first half of 2026.
• Gross profit margin improved to 63.3% in Q2 2026 and 64.2% in the first half of 2026.
• Income from operations dramatically increased by 387.7% to $7.0 million in Q2 2026 and by 248.4% to $13.7 million in the first half of 2026.
• Operating cash flow was a strong $20.1 million for the first six months of 2026, a significant turnaround from a negative $2.4 million in the prior year.
• The company ended the period with $27.4 million in available cash (excluding restricted cash), up from $11.8 million in the prior year.
• The pharma industry segment experienced revenue growth of 88.9% in Q2 2026 and 85.2% in the first half of 2026.
• Gross dollar volume loaded on cards increased by 23.0% for the plasma industry and 85.2% for the pharma industry in the first half of 2026.

Negatives

• Cost of revenues increased by 41.4% in Q2 2026 and 41.8% in the first half of 2026, largely due to increased call center support, sales commissions, and network fees.
• Selling, general, and administrative expenses increased by 4.3% in Q2 2026 and 11.9% in the first half of 2026, driven by higher compensation, benefits, and stock-based compensation.
• Amortization of intangible assets from the Gamma acquisition and continued software development contributed to a 10.4% increase in depreciation and amortization expense for Q2 2026.
• The company's accounts receivable increased significantly by $30.9 million in the first half of 2026, primarily related to the growth in its pharma patient affordability business and timing of pass-through payments.

Risks

• If a certain financial institution were to be placed into receivership, the company may be unable to access its cash on deposit, potentially adversely affecting its financial position and ability to operate.
• The company has a concentration of accounts receivable risk, with one pharma patient affordability customer representing 36% of accounts receivable at June 30, 2026.
• Third-party software may be used for highly specialized business functions, which the company may not be able to develop internally within time and budget constraints.
• The company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business, and an adverse result could harm its business.

Future Outlook

The company believes its available cash, combined with forecasted revenues and cash flows through the second quarter of 2028, will be sufficient to sustain operations for the next twenty-four months. They plan to continue investing in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance throughout 2026. The company also evaluates raising capital to diversify into new market verticals, but believes it can support existing business and expand using internally generated funds if new capital is not raised.

Management Comments

• The plasma market appears to have returned to normalized growth following elevated plasma inventory levels experienced throughout much of 2025.
• We believe our available cash on hand, excluding restricted cash, together with our forecast for revenues and cash flows for the remainder of 2026 and through the second quarter of 2028, will be sufficient to sustain our operations for the next twenty-four months.
• We plan to continue to invest additional funds in technology improvements, sales and marketing, cybersecurity, fraud, customer service and regulatory compliance during the remainder of 2026.
• From time to time, we evaluate raising capital to enable us to diversify into new market verticals. If we do not raise new capital, we believe that we will still be able to support our existing business and expand into new vertical markets using internally generated funds.

Industry Context

StockSavvy.ai notes that Paysign's strong performance aligns with a recovering plasma market and continued growth in the pharma patient affordability sector, indicating a favorable environment for their specialized payment solutions. The company's focus on technology integration and scalability positions it well within the evolving fintech landscape.

Comparison to Industry Standards

• Paysign's revenue growth of 48.1% in Q2 2026 significantly outpaces the general fintech sector's growth rates, which have seen more moderate expansion in recent periods.
• The company's net income margin of 23.9% for Q2 2026 is robust and compares favorably to many payment processing companies, especially those with similar business models.
• The improvement in gross profit margin to 63.3% suggests efficient cost management relative to revenue generation, a key indicator of operational strength in the payment processing industry.
• The substantial increase in Gross Dollar Volume loaded on cards, particularly in the plasma and pharma segments, indicates strong customer adoption and transaction activity, which is a positive sign for companies in this space.

Legal Proceedings

• The company is not currently a party to any pending or threatened legal proceedings that it believes could have a material adverse effect on its business or financial condition.

Related Party Transactions

• In the first quarter of 2025, the company hired an employee who is also the principal owner of a technical consulting corporation engaged by the Company to provide technology, development, and support services. Related party expenses were $170,860 for Q2 2026 and $331,693 for the first half of 2026, compared to $79,000 for the same periods in 2025.

Stakeholder Impact

• Shareholders are likely to benefit from the significant increase in net income and improved financial performance, potentially leading to increased shareholder value.
• Employees may see continued investment in compensation, benefits, and stock-based awards to support growth and retention.
• Customers in the plasma and pharma industries are benefiting from improved services and affordability solutions, with continued investment in platform enhancements.
• Suppliers may experience increased business due to higher transaction volumes and program growth, particularly in the pharma patient affordability sector.

Next Steps

• Continue investing in technology improvements, sales and marketing, cybersecurity, fraud prevention, customer service, and regulatory compliance throughout 2026.
• Evaluate raising capital to diversify into new market verticals.
• Seek stockholder approval at the next annual meeting (expected on or before June 30, 2027) for an increase in authorized shares under the 2023 Equity Incentive Plan.
• Continue to monitor the health and soundness of bank relationships.

Key Dates

Recommendation

The filing demonstrates exceptionally strong financial performance with significant revenue and net income growth, improved margins, and positive operating cash flow. The company's strategic focus on growing segments like pharma patient affordability and the recovery in the plasma market, coupled with ongoing investment in technology and sales, suggests a positive trajectory. While there are minor cost increases, they are largely in line with growth, and the company's liquidity position is strong. The overall outlook is very favorable, supporting a 'buy' recommendation.

Keywords

prepaid card, payment processing, pharma patient affordability, plasma industry, revenue growth, financial results, gross dollar volume, net income